Presentation is loading. Please wait.

Presentation is loading. Please wait.

Significance of Extrapolation of Foreign Clinical Data to Asian Countries Masahiro Takeuchi Div. of Biostatistics Kitasato University Graduate School The.

Published bySarah Martin Modified over 9 years ago

Similar presentations

Presentation on theme: "Significance of Extrapolation of Foreign Clinical Data to Asian Countries Masahiro Takeuchi Div. of Biostatistics Kitasato University Graduate School The."— Presentation transcript:

1 Significance of Extrapolation of Foreign Clinical Data to Asian Countries Masahiro Takeuchi Div. of Biostatistics Kitasato University Graduate School The 2nd Kitasato-Harvard Symposium, 10/22/01

2 Acknowledgment Bridging Study Working Group* Div. of Biostatistics Kitasato University Graduate School Kazuhiro Abe, Isao Kawachi, Masahiro Takeuchi, Masako Nishikawa, Keiichiro Hirose, Yoshiharu Horie, Kazuhiro Matsui

3 Outline Introduction E5 Guideline Application of E5 Guideline from Statistical Point of View Future Application

4 Introduction ICH - General Purpose –Unification of Necessary Documentation and its Formats for NDA Submission ICH - Extrapolation –Avoidance of Unnecessary Clinical Trials Ethically Speaking Globalization –Good Drugs in a Faster Time

5 Conditions for Extrapolation Two factors –Intrinsic Factors –Extrinsic Factors

6 Review of Two Factors (APPENDIX A) Intrinsic Factors –Genetic: race, drug metabolism, genetic diseases –Physiological and pathological conditions: Age ( children-elderly), Liver, Kidney, Cardiovascular functions, Diseases Extrinsic Factors –Culture, Medical Practice, Regulatory practice/GCP, Methodology/Endpoints

7 Implication of Two Factors Intrinsic Factors –Do we have an clearly defined comparative population to targeted/existed foreign population? Extrinsic Factors –Can we conduct a planned clinical trial ?

8 Application of E5 Guideline Target Disease Population Sample US EU US Intrinsic factors No Yes Extrinsic Factors No Yes EU NR Necessary Conditions Necessary Conditions Part I Part II Part III Part IV

9 Application of E5 Guideline: Part I Target Disease Population Sample Clinical Trial (y 1, y 2, …, y n ) Estimation of Efficacy Two Major Concerns: (i) high quality protocol (ii) high quality of data Regulatory review system GCP

10 Application of E5 Guideline: Part II Intrinsic Factors No EUUSNR Sample from EU Sample from US Sample from NR (y EU1, y EU2, …, y EUn1 ) (y US1, y US2, …, y USn2 ) (y NR1, y NR2, …, y NRn3 ) Sample from a Same Probability Space Genetic variation

11 Application of E5 Guideline: Part III Intrinsic Factors EU NR US Yes Question: Are these samples (EU, US, and NR) derived from a same target disease population? Answer: No Need adjustment for intrinsic factors to have a common population among three regions Genetic variation

12 Application of E5 Guideline: Part IV Extrinsic Factors NoYes Necessary conditions Quality Control - Protocol Review System - GCP Safety Issues - surveillance Conduct of suitable clinical trials subject to medical practice, clinical trial environment Study Design - placebo vs active - choice of endpoint Language& culture - subsets of primary endpoint

13 Future Application: Past Experience Western Data Region 1Region 2Region 3 (i) No clear scientific evidence regarding racial difference (ii) No clear statistical approach - similarity, sample size (iii) No unified regulatory authority requirements Bridging Study 1Bridging Study 2Bridging Study 3

14 (i) Scientific Evidence NEJM - Two drugs in heart failure May 3, 2001 - Two editorials Importance of pharmacogenomics (ii) Statistical Evidence Shih ､ Lui - Consistency among trials Ware, Morris - Empirical Bayes Akahira and Takahashi, Takeuchi - Consistency by bootstrap Homogeneous target population Clear definition of efficacy Statistical approach/Sample size (iii) Regulatory Requirements APEC Meeting in Taiwan in May,01 Quality control of trials - Regulatory review system - GCP

15 Future Application Western Data Similar regions Region 1Region 2Region 3 Similar region: - Intrinsic factors - Extrinsic factors (medical practice, clinical trial environment,etc) - GCP

16 Future Challenge EU US Asia (i) one global protocol - def. of target population - def. of expected efficacy - study design (ii) modification subject to - intrinsic factors - extrinsic factors (iii) quality control of trials - protocol review - GCP Clear def. of probability space Target Disease Pop. Each sample derived from the PS Quality assurance

17 Good Drugs in a Faster Time Correctly Targeted Disease Population Thoroughly Planned and Collected Sample High Quality Data

Download ppt "Significance of Extrapolation of Foreign Clinical Data to Asian Countries Masahiro Takeuchi Div. of Biostatistics Kitasato University Graduate School The."

Similar presentations

Issues on Recent Drug Development in Japan

Issues on Recent Drug Development in Japan
Bridging Studies Global Development W. Joe Shih Biostatistics Dept UMDNJ-School of Public Health Sept. 29, 2006 FDA/Industry Conference, Washington D.C.

Bridging Studies Global Development W. Joe Shih Biostatistics Dept UMDNJ-School of Public Health Sept. 29, 2006 FDA/Industry Conference, Washington D.C.
Global Drug Development To Bridge or Not to Bridge.

Global Drug Development To Bridge or Not to Bridge.
Implementation of Bridging Study-Taiwans Experience Meir-Chyun Tzou, Ph.D. Senior Officer, and Director of Section III, Bureau of Pharmaceutical Affairs.

Implementation of Bridging Study-Taiwans Experience Meir-Chyun Tzou, Ph.D. Senior Officer, and Director of Section III, Bureau of Pharmaceutical Affairs.
Robert T. O’Neill, Ph.D. Director, Office of Biostatistics CDER, FDA

Robert T. O’Neill, Ph.D. Director, Office of Biostatistics CDER, FDA
1 WORKSHOP 4: KEY COMMENTS FROM THE PANEL DISCUSSION The 3rd Kitasato University - Harvard School of Public Health Symposium Wednesday October 2nd - Thursday.

1 WORKSHOP 4: KEY COMMENTS FROM THE PANEL DISCUSSION The 3rd Kitasato University - Harvard School of Public Health Symposium Wednesday October 2nd - Thursday.
Development of Evaluation and Consultation on Bridging Studies: Thailand Experiences Suchart Chongprasert, Ph.D. Investigational New Drug Subdivision Food.

Development of Evaluation and Consultation on Bridging Studies: Thailand Experiences Suchart Chongprasert, Ph.D. Investigational New Drug Subdivision Food.
E5 Experiences in Japan Examples with unfavorable outcome How can we improve? Masuhiro Kato, PhD Chair, EFPIA Japan Technical Subcommittee (AstraZeneca.

E5 Experiences in Japan Examples with unfavorable outcome How can we improve? Masuhiro Kato, PhD Chair, EFPIA Japan Technical Subcommittee (AstraZeneca.
Use of Foreign Data for Approval Ann Farrell, MD Division of Oncology Drug Products Center for Drug Evaluation and Research Food and Drug Administration.

Use of Foreign Data for Approval Ann Farrell, MD Division of Oncology Drug Products Center for Drug Evaluation and Research Food and Drug Administration.
The ICH E5 Guidance: An Update on Experiences with its Implementation The ICH E5 Guidance: An Update on Experiences with its Implementation Robert T. O’Neill,

The ICH E5 Guidance: An Update on Experiences with its Implementation The ICH E5 Guidance: An Update on Experiences with its Implementation Robert T. O’Neill,
ICH E-5 Overview and Current Topics Mamoru Narukawa.

ICH E-5 Overview and Current Topics Mamoru Narukawa.
4 th Kitasato-Harvard Symposium: Summary and Conclusions Stephen Lagakos Harvard School of Public Health.

4 th Kitasato-Harvard Symposium: Summary and Conclusions Stephen Lagakos Harvard School of Public Health.
K. Shimatani/ K-H Symposium/ October 22-23, 20011 What Impact Will Globalization Have on Bridging Studies Katsuyoshi Shimatani J-Clin, Pfizer.

K. Shimatani/ K-H Symposium/ October 22-23, What Impact Will Globalization Have on Bridging Studies Katsuyoshi Shimatani J-Clin, Pfizer.
2nd Kitasato-Harvard 23/10/2001 Toward Regional Multi-Centered Trials Daisaku Sato Evaluation and Licensing Division Ministry of Health, Labour and Welfare.

2nd Kitasato-Harvard 23/10/2001 Toward Regional Multi-Centered Trials Daisaku Sato Evaluation and Licensing Division Ministry of Health, Labour and Welfare.
Many Important Issues Covered Current status of ICH E5 and implementation in individual Asian countries Implementation at a regional level (EU) and practical.

Many Important Issues Covered Current status of ICH E5 and implementation in individual Asian countries Implementation at a regional level (EU) and practical.
Basic Design Consideration. Previous Lecture Definition of a clinical trial The drug development process How different aspects of the effects of a drug.

Basic Design Consideration. Previous Lecture Definition of a clinical trial The drug development process How different aspects of the effects of a drug.
Some Closing Remarks. Scope of Symposium Simultaneous Worldwide Development Strategies & Pharmacogenomics: 6 Sessions –1. Overview: Drs. Yazaki; Fujiwara,

Some Closing Remarks. Scope of Symposium Simultaneous Worldwide Development Strategies & Pharmacogenomics: 6 Sessions –1. Overview: Drs. Yazaki; Fujiwara,
ODAC May 3, 2004 1 Subgroup Analyses in Clinical Trials Stephen L George, PhD Department of Biostatistics and Bioinformatics Duke University Medical Center.

ODAC May 3, Subgroup Analyses in Clinical Trials Stephen L George, PhD Department of Biostatistics and Bioinformatics Duke University Medical Center.
1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.

1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

Similar presentations

Ads by Google